Avalo Therapeutics Inc. WKN: A3E2FR ISIN: US05338F3064 Kürzel: AVTX Forum: Aktien User: KleinerFuchs

Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX), noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurativa (HS) and additional updates. In March, Avalo Therapeutics announced the acquisition of a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, originally developed by Eli Lilly And Co (NYSE:LLY). Avalo announced a private placement of $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million. Oppenheimer says that the company is preparing to advance ‘009 for Phase 2 development in hidradenitis suppurativa (HS), showing confidence in its potential. While topline data won’t be available until 2026, there’s consideration to also evaluate ‘009 for ulcerative colitis (UC), which could provide interim updates. The analyst has upgraded to Outperform from Perform, setting a $35 price target based on the belief that AVTX-009 could stand out in the competitive HS market.